Skip to main
ARCT
ARCT logo

Arcturus Therapeutics (ARCT) Stock Forecast & Price Target

Arcturus Therapeutics (ARCT) Analyst Ratings

Based on 22 analyst ratings
Buy
Strong Buy 41%
Buy 32%
Hold 14%
Sell 5%
Strong Sell 9%

Bulls say

Arcturus Therapeutics Holdings Inc. is poised for significant growth, driven by the recent approval of new manufacturing sites in Japan alongside its joint venture, which aims to bolster production capabilities for its mRNA medicines. With clinical data expected in 2025 from its proprietary mRNA programs, there is potential for a revenue projection exceeding $500 million five years post-launch, particularly with a potential approval in the European Union that could enhance its market capitalization. Additionally, the involvement of CSL Seqirus, a seasoned vaccine developer, to lead commercialization efforts mitigates execution risks and positions Arcturus favorably within the lucrative cystic fibrosis market, which has demonstrated substantial revenue examples like TRIKAFTA.

Bears say

Arcturus Therapeutics Holdings Inc. is experiencing a negative outlook primarily due to significant revisions in revenue projections, which have been drastically lowered from $156.4 million to $11.8 million for its Kostaive product based on disappointing market estimates for COVID-19 vaccinations in Japan. In addition, the company's net loss for 4Q24 was reported at $30 million, reflecting ongoing operational challenges as it concludes the quarter with approximately $294 million in cash and equivalents, raising concerns about its ability to fund future operations. Furthermore, the overall valuation of Arcturus remains highly contingent on the success of its lead asset, ARCT-154, alongside potential delays and regulatory risks related to its mRNA therapies, which collectively contribute to a bleak financial outlook.

Arcturus Therapeutics (ARCT) has been analyzed by 22 analysts, with a consensus rating of Buy. 41% of analysts recommend a Strong Buy, 32% recommend Buy, 14% suggest Holding, 5% advise Selling, and 9% predict a Strong Sell.

This aggregate rating is based on analysts' research of Arcturus Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Arcturus Therapeutics (ARCT) Forecast

Analysts have given Arcturus Therapeutics (ARCT) a Buy based on their latest research and market trends.

According to 22 analysts, Arcturus Therapeutics (ARCT) has a Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $46.22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $46.22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Arcturus Therapeutics (ARCT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.